Emergent BioSolutions Inc. (EBS) compared with its closest peers (CAMP, ELDN, ALXO, ZNTL, IMRN): P/E 2.3 vs industry 17.2. Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| CAMP4 Therapeutics Corporation (CAMP) | $280.51M | -2.3 |
| Eledon Pharmaceuticals, Inc. (ELDN) | $279.13M | -2.9 |
| ALX Oncology Holdings Inc. (ALXO) | $273.84M | -0.6 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | $271.93M | -0.7 |
| Immuron Limited (IMRN) | $271.39M | — |
| Q32 Bio Inc. (QTTB) | $270.79M | 1.4 |
| vTv Therapeutics Inc. (VTVT) | $270.06M | 119.9 |
| MacroGenics, Inc. (MGNX) | $257.35M | -1.4 |
| Pyxis Oncology, Inc. (PYXS) | $256.06M | -0.9 |
| Nature's Sunshine Products, Inc. (NATR) | $252.32M | 13.2 |
| Stock P/E | 2.3 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | -89.4% |
| vs Industry | -86.6% |
EBS overview · EBS earnings · EBS financials · EBS KPIs · EBS investor relations · EBS ownership · EBS filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.